US Cycle Control and Blood Pressure Study

PHASE3CompletedINTERVENTIONAL
Enrollment

346

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions
Contraception
Interventions
DRUG

Gestodene/EE (FC Patch Low, BAY86-5016)

21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2

DRUG

Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A

21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1

Trial Locations (28)

15090

Wexford

15206

Pittsburgh

19114

Philadelphia

23294

Richmond

27103

Winston-Salem

29201

Columbia

30034

Decatur

30342

Atlanta

32114

Daytona Beach

33169

Miami

33461

Lake Worth

33759

Clearwater

34748

Leesburg

45246

Cincinnati

49009

Kalamazoo

54691

La Crosse

63141

St Louis

70006

Metairie

85032

Phoenix

85304

Glendale

85712

Tucson

89104

Las Vegas

92121

San Diego

92801

Anaheim

98055

Renton

98105

Seattle

85225-2909

Chandler

08901

New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00920985 - US Cycle Control and Blood Pressure Study | Biotech Hunter | Biotech Hunter